About
Epicrispr Biotechnologies is a biotechnology company developing ultracompact therapies to modulate gene expression in vivo using the smallest known Cas protein, CasMINI.
Focus
Lease
Markets
FAQs
Epicrispr Biotechnologies has financed 1 deal.
Epicrispr Biotechnologies's most recent deal was on April 23, 2026.
Member since: April 2026
Deals
Transaction Type
Asset Type
State
Sort By
LEASED
Amber Salzman Of CBRE Represents Epicrispr Biotechnologies In 24,780 Square Foot Lease Renewal In South San Francisco
7000 Shoreline Court, South San Francisco, CA
CACRE
Apr 23, 2026